MCID: CLL014
MIFTS: 46

Cll/sll

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Cll/sll

MalaCards integrated aliases for Cll/sll:

Name: Cll/sll 12 15
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma 12 74

Classifications:



External Ids:

Disease Ontology 12 DOID:6354
NCIt 51 C27911
UMLS 74 C1302547

Summaries for Cll/sll

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.

MalaCards based summary : Cll/sll, also known as chronic lymphocytic leukemia/small lymphocytic lymphoma, is related to lymphoma and lymphoma, hodgkin, classic, and has symptoms including fatigue An important gene associated with Cll/sll is ZAP70 (Zeta Chain Of T Cell Receptor Associated Protein Kinase 70), and among its related pathways/superpathways are DNA Damage Response and Cell cycle. The drugs rituximab and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Decreased TP53 mRNA expression and cellular

Related Diseases for Cll/sll

Diseases related to Cll/sll via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 lymphoma 30.7 ATM CCND1 EZH2 PAX5
2 lymphoma, hodgkin, classic 30.3 CD5 MME PAX5
3 diffuse large b-cell lymphoma 30.1 CD5 EZH2 MME TP53
4 acute lymphocytic leukemia 30.0 MME PAX5 TP53
5 composite lymphoma 29.9 CD5 PAX5 SOX11
6 richter's syndrome 29.8 ATM CD38 CD5 TP53
7 b-cell lymphomas 29.8 CCND1 CD5 MME PAX5 TP53
8 marginal zone b-cell lymphoma 29.7 CCND1 CD5 MME SLC35B2
9 leukemia, chronic lymphocytic 29.6 ATM CCND1 CD38 CD5 PAX5 TP53
10 lymphocytic leukemia 29.6 ATM CD38 CD5 MME PAX5 TP53
11 lymphoma, non-hodgkin, familial 28.5 ATM CCND1 CD38 CD5 MME PAX5
12 mantle cell lymphoma 28.3 ATM CCND1 CD5 EZH2 MME PAX5
13 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.5
14 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.5
15 leukemia, chronic lymphocytic 2 10.7
16 leukemia 10.7
17 leukemia, b-cell, chronic 10.7
18 follicular lymphoma 10.3
19 sarcoma 10.3
20 lymphadenitis 10.3
21 melanoma 10.3
22 lymphomatoid papulosis 10.3
23 myxosarcoma 10.3 ATM TP53
24 cd45 deficiency 10.3 CD5 ZAP70
25 peripheral t-cell lymphoma 10.2
26 diarrhea 10.2
27 herpes simplex 10.2
28 non-proliferative fibrocystic change of the breast 10.2 CCND1 TP53
29 necrotizing sialometaplasia 10.2 CD5 TP53
30 oral leukoplakia 10.2 CCND1 TP53
31 cervical carcinosarcoma 10.2 MME TP53
32 adenosarcoma 10.2 MME TP53
33 central nervous system hematologic cancer 10.2 MME TP53
34 verrucous carcinoma 10.2 CCND1 TP53
35 tracheal lymphoma 10.2 CD5 MME
36 breast benign neoplasm 10.2 MME TP53
37 thoracic benign neoplasm 10.2 MME TP53
38 eccrine sweat gland neoplasm 10.2 MME TP53
39 intravascular large b-cell lymphoma 10.2 CD5 MME
40 hidradenocarcinoma 10.2 CCND1 TP53
41 mutagen sensitivity 10.2 CCND1 TP53
42 pre-malignant neoplasm 10.1 CCND1 TP53
43 mixed cell type cancer 10.1 MME TP53
44 keratocystic odontogenic tumor 10.1 CCND1 TP53
45 pancreatic mucinous cystadenoma 10.1 EZH2 MME
46 anemia, autoimmune hemolytic 10.1
47 thymoma, familial 10.1
48 neutrophilic dermatosis, acute febrile 10.1
49 endometrial cancer 10.1
50 leukemia, acute lymphoblastic 10.1

Graphical network of the top 20 diseases related to Cll/sll:



Diseases related to Cll/sll

Symptoms & Phenotypes for Cll/sll

UMLS symptoms related to Cll/sll:


fatigue

GenomeRNAi Phenotypes related to Cll/sll according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased TP53 mRNA expression GR00389-S-5 8.62 ATM TP53

MGI Mouse Phenotypes related to Cll/sll:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 ATM CCND1 CD38 EZH2 PAX5 SOX11
2 hematopoietic system MP:0005397 9.97 ATM CCND1 CD38 CD5 EZH2 PAX5
3 immune system MP:0005387 9.96 ATM CCND1 CD38 CD5 EZH2 MME
4 endocrine/exocrine gland MP:0005379 9.91 ATM CCND1 CD38 EZH2 SOX11 TP53
5 integument MP:0010771 9.76 ATM CCND1 CD5 EZH2 MME SOX11
6 neoplasm MP:0002006 9.35 ATM CCND1 EZH2 PAX5 TP53
7 normal MP:0002873 9.17 CCND1 CD5 EZH2 PAX5 SOX11 TP53

Drugs & Therapeutics for Cll/sll

Drugs for Cll/sll (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 75607-67-9, 21679-14-1 30751
3
ofatumumab Approved Phase 3,Phase 1,Phase 2 679818-59-8 6918251
4
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
5 Immunologic Factors Phase 3,Phase 2,Phase 1
6 Antirheumatic Agents Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
8 Alkylating Agents Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 2, Phase 3,Phase 1
11 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
12 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
13 tyrosine Phase 3,Phase 1,Phase 2
14 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
15 Immunoglobulins Phase 3,Phase 1,Phase 2
16 Antibodies Phase 3,Phase 1,Phase 2
17 Bendamustine Hydrochloride Phase 3,Phase 2,Phase 1
18 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
19 Anti-Retroviral Agents Phase 3,Phase 1
20 Anti-HIV Agents Phase 3,Phase 1
21 Antiviral Agents Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1
23 Zanubrutinib Phase 3,Phase 1,Phase 2
24 Reverse Transcriptase Inhibitors Phase 3
25 Nucleic Acid Synthesis Inhibitors Phase 3
26
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
27
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
28
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
29
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
30
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
31
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0
32
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
33
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
35
Adenosine Approved, Investigational Phase 2,Phase 1 58-61-7 60961
36
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
37
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560 441411
38
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
39
Venetoclax Approved, Investigational Phase 1, Phase 2,Phase 2 1257044-40-8 49846579
40
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
41
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
42
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
43
Obinutuzumab Approved, Investigational Phase 1, Phase 2,Phase 2 949142-50-1
44
Allopurinol Approved Phase 2 315-30-0 2094
45
nivolumab Approved Phase 2,Phase 1 946414-94-4
46
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492 6473866
47
Melphalan Approved Phase 2 148-82-3 460612 4053
48
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
49
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
50
Busulfan Approved, Investigational Phase 2 55-98-1 2478

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
2 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
4 A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting NCT03336333 Phase 3 BGB-3111;Bendamustine;Rituximab
5 Tenofovir to Prevent HBV Reactivation Recruiting NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
6 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Active, not recruiting NCT02004522 Phase 3 Duvelisib;Ofatumumab
7 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 Enrolling by invitation NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
8 Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Terminated NCT00714259 Phase 2, Phase 3 Fludarabine
9 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
10 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed NCT00974233 Phase 2 Bendamustine;Rituximab;Lenalidomide
11 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
12 Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01002755 Phase 2 Lenalidomide
13 A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia Completed NCT01403636 Phase 2 SAR245409
14 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00280241 Phase 2 Fludarabine;Cyclophosphamide;Rituximab
15 Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00193518 Phase 2 Arsenic Trioxide
16 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
17 Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Completed NCT00201682 Phase 1, Phase 2 Etanercept;Rituximab
18 Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00193466 Phase 2 Rituximab;Fludarabine;CAMPTH-1H
19 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00439231 Phase 2 Lenalidomide
20 Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00290004 Phase 1, Phase 2 motexafin gadolinium
21 Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00873457 Phase 2 perifosine
22 Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00935792 Phase 1, Phase 2 alemtuzumab;everolimus
23 Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01024010 Phase 2 Cyclophosphamide;Pentostatin
24 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00669318 Phase 2 pentostatin;sargramostim
25 Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00090090 Phase 2 Elsamitrucin
26 Safety of PCI-32765 in Chronic Lymphocytic Leukemia Completed NCT01105247 Phase 1, Phase 2 PCI-32765
27 A Study to Investigate ICP-022 in Chinese Patients With CLL/ SLL Recruiting NCT03493217 Phase 1, Phase 2 ICP-022
28 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting NCT03740529 Phase 1, Phase 2 LOXO-305
29 Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Recruiting NCT03379051 Phase 1, Phase 2 Venetoclax;Umbralisib;Ublituximab
30 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT02514083 Phase 2 Ibrutinib;Fludarabine
31 Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Recruiting NCT03788291 Phase 2 Acalabrutinib;Rituximab
32 Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT01066663 Phase 1, Phase 2 pyrimethamine
33 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT03204188 Phase 2 Ibrutinib;Fludarabine;Pembrolizumab
34 MB-CART2019.1 Lymphoma Recruiting NCT03870945 Phase 1, Phase 2
35 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Recruiting NCT01754857 Phase 2 Bendamustine;Rituximab;Lenalidomide
36 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting NCT03010358 Phase 1, Phase 2 Entospletinib
37 Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting NCT03516617 Phase 2 Acalabrutinib
38 Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers Recruiting NCT03037645 Phase 1, Phase 2 SNS-062
39 Phase 1/2A Dose Escalation Study in CLL, SLL or NHL Recruiting NCT01994382 Phase 1, Phase 2 Cerdulatinib (PRT062070)
40 Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Recruiting NCT03045328 Phase 2 Ibrutinib;Venetoclax
41 Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Recruiting NCT03041636 Phase 2 Ruxolitinib
42 Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Recruiting NCT03128879 Phase 2 Venetoclax;Ibrutinib;Allopurinol
43 Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting NCT02420912 Phase 2 Nivolumab;Ibrutinib
44 HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) Recruiting NCT03685708 Phase 2
45 Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Recruiting NCT03572634 Phase 1, Phase 2 TP-0903
46 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Recruiting NCT02988466 Phase 2 GVHD Prophylaxis
47 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Recruiting NCT03128359 Phase 2 Busulfan;Cyclophosphamide;Fludarabine Phosphate;Melphalan Hydrochloride;Mycophenolate Mofetil;Tacrolimus
48 A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Active, not recruiting NCT02135133 Phase 2 Idelalisib;Ofatumumab
49 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT02225275 Phase 2 Lenalidomide;Obinutuzumab
50 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT01497496 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide

Search NIH Clinical Center for Cll/sll

Genetic Tests for Cll/sll

Anatomical Context for Cll/sll

MalaCards organs/tissues related to Cll/sll:

42
B Cells, Bone, Bone Marrow, Lymph Node, T Cells, Myeloid, Kidney

Publications for Cll/sll

Articles related to Cll/sll:

(show top 50) (show all 149)
# Title Authors Year
1
Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. ( 30650954 )
2019
2
The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients. ( 30718223 )
2019
3
A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 30734348 )
2019
4
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. ( 30659125 )
2019
5
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
6
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
7
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
8
Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. ( 29289901 )
2018
9
EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. ( 30031020 )
2018
10
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. ( 30287523 )
2018
11
Pericardial Involvement with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Constrictive Pericarditis. ( 30140781 )
2018
12
Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30155841 )
2018
13
An Unusual Coexistence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with Endometrioid-Type Endometrial Cancer in a 58-Year-Old Woman: A Case Study with Literature Review. ( 29928215 )
2018
14
Hypercalcemia and osteolytic bone lesions as the major symptoms in a chronic lymphocytic leukemia/small lymphocytic lymphoma patient: a rare case. ( 30416172 )
2018
15
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 30315239 )
2018
16
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30249389 )
2018
17
Lymphomatoid papulosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and literature review. ( 30142733 )
2018
18
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( 30061088 )
2018
19
A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 29740389 )
2018
20
Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 29170253 )
2018
21
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. ( 29295653 )
2018
22
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( 28714377 )
2018
23
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 28109040 )
2018
24
CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27221715 )
2018
25
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
26
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
27
An unusual case of chronic diarrhea: chronic lymphocytic leukemia/small lymphocytic lymphoma with colorectal involvement. ( 28511955 )
2017
28
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
29
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. ( 28592889 )
2017
30
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
31
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
32
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. ( 28373262 )
2017
33
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. ( 28718694 )
2017
34
Lymphomatoid papulosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma: 3 cases. ( 28569995 )
2017
35
Comparison of chromosomal rearrangements in bone marrow cells and blast transformed B-cells in relapse of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 29483496 )
2017
36
Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28802891 )
2017
37
Feasibility of Counting Smudge Cells as Lymphocytes in Differential Leukocyte Counts Performed on Blood Smears of Patients With Established or Suspected Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28371883 )
2017
38
An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology. ( 27919167 )
2017
39
CLL/SLL with initial presentation as a longstanding cutaneous plaque: A rare case. ( 27147484 )
2016
40
Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K). ( 26740820 )
2016
41
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27324214 )
2016
42
Proliferation centers in bone marrows involved by chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic analysis. ( 27806839 )
2016
43
Bilateral Tonsillar Enlargement as a First Manifestation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with an Unusual Interfollicular Pattern of Infiltration. ( 27408379 )
2016
44
Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27414262 )
2016
45
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 27081879 )
2016
46
A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 26390065 )
2016
47
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. ( 26699397 )
2016
48
A Man With Chronic Lymphocytic Leukemia and Declining Kidney Function. Native kidney BK nephropathy and chronic lymphocytic leukemia/small lymphocytic lymphoma infiltration with chronic tubulointerstitial damage resulting in worsening kidney function. ( 26708199 )
2016
49
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 26764527 )
2016
50
Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 25795422 )
2015

Variations for Cll/sll

Expression for Cll/sll

Search GEO for disease gene expression data for Cll/sll.

Pathways for Cll/sll

Pathways related to Cll/sll according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.13 ATM CCND1 TP53
2 12.11 ATM CCND1 TP53
3 12.1 ATM CCND1 EZH2 TP53
4
Show member pathways
12.09 ATM CCND1 TP53
5 11.99 ATM PAX5 TP53
6
Show member pathways
11.97 ATM CCND1 TP53
7 11.87 ATM CCND1 TP53
8 11.84 ATM CCND1 TP53
9 11.67 CD38 CD5 MME
10 11.64 ATM CCND1 TP53
11 11.53 CD38 CD5 MME
12 11.31 ATM TP53 ZAP70
13 11.13 ATM CCND1 TP53
14 11.02 ATM TP53
15 10.98 ATM CCND1 TP53
16
Show member pathways
10.85 ATM TP53
17 10.74 ATM TP53
18 10.65 CD38 CD5 MME PAX5
19 10.64 ATM CCND1 TP53

GO Terms for Cll/sll

Biological processes related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.65 CCND1 EZH2 PAX5 SOX11 TP53
2 positive regulation of cell proliferation GO:0008284 9.62 CCND1 CD38 EZH2 SOX11
3 liver regeneration GO:0097421 9.4 CCND1 EZH2
4 cellular response to gamma radiation GO:0071480 9.37 ATM TP53
5 response to estradiol GO:0032355 9.33 CCND1 CD38 EZH2
6 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
7 replicative senescence GO:0090399 8.8 ATM MME TP53

Molecular functions related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 8.92 EZH2 PAX5 SOX11 TP53

Sources for Cll/sll

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....